Capture Vascular Receives CE Mark Approval

Capture Vascular, Inc. (Capture), a Telluride Medical Partners company, announced today that it has received CE (Conformité Européenne) marking for its proprietary MegaVac Mechanical Thrombectomy System.
 
“The CE mark is a critical milestone for Capture; the team has been working on its issuance since mid-2017,” stated Eric Wells, CEO of Capture. “We can now launch our sales efforts in Europe, a market that has expressed great interest in Capture’s technology,” stated Wells.
 
Capture is currently in early discussions with a number of European distribution partners, has a few agreements in place, and is working diligently to finalize additional agreements now that the CE mark has been issued.

“We are confident that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists throughout Europe will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” stated Wells.

Capture’s proprietary technology includes key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen.

Founded in 2013, Capture’s proprietary technology includes the MegaVac Catheter with SafeSeal Technology and the ThromboWire Clot Retractor, which makes up the MegaVac Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

TMP is a Resident Company at Johnson & Johnson Innovation, JLABS

Telluride Medical Partners announced today that it is now a Resident Company at Johnson & Johnson Innovation, JLABS (JLABS) at the prestigious Texas Medical Center—the world’s largest cancer center—located in Houston, TX (JLABS @ TMC).

“We are thrilled to be part of an elite program dedicated to innovation and the advancement of startup medical companies and technologies,” stated Eric Wells, Founder & CEO of TMP.

JLABS is a 34,000 square-foot life science innovation center located at the Texas Medical Center in Houston, TX. The labs provide a flexible environment for startup companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products, either on their own, or, by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

“Having a presence at JLABS @ TMC will provide Telluride Medical Partners with a concentrated set of unmatched opportunities that can help advance each of our companies and technologies,” stated Wells.

TMP Secures $2.2 Million in New Financing

Telluride Medical Partners (TMP) announced today that it has secured $2.2 million in new financing that will be invested into TMP’s portfolio of companies.
 
The new financing comes from two investors and closed at the end of 2017, with a large portion coming from a private individual with a family office in Houston, Texas that invests in energy, real estate and medical, among other industries. The second investment came from Regis Medical, a German company that specializes in the commercialization and distribution of high-quality and innovative medical device products.
 
“We are excited to have two new investors involved with TMP who both bring their own set of industry connections to help advance TMP and its portfolio of companies,” stated Eric Wells, CEO and Founder of Telluride Medical Partners. “This new funding will go towards the continued development and commercialization of each company’s disruptive medical device technology,” stated Wells.
 
TMP continues to attract interest from partners and investors alike and the team is focused on further exposing its companies by attending elite industry conferences and networking events.
 
“We received a great amount of interest from strategic partners and investors from around the world while attending meetings at the recent J.P. Morgan Healthcare Conference in San Francisco,” stated Wells. “As we continue to advance each company it is imperative to stay connected with medical device experts and industry influencers to continue to drive interest and market our companies. We look forward to cultivating these new relationships in the coming weeks,” stated Wells.

TMP’s portfolio of companies is impressive to say the least.

Capture Vascular’s proprietary thrombectomy system, the MegaVacTM Mechanical Thrombectomy System, is a disruptive technology that offers several unique features in one simple device such as centering and securing the occlusion funnel tip position within the vessel, as well as being able to pass other lesion disruptive devices through its lumen. Its unique design and broad indications for use makes it appropriate for several key markets with a total worldwide market opportunity greater than $500M.
 
Nectero Medical focuses on the development of the disruptive early-stage treatment of abdominal aortic aneurysms (AAA), and has developed a patented compound called pentagalloyl glucose that stabilizes elastin and improves tissue strength that can be used as early treatment for patients living with AAA. Nectero Medical’s potential customers include the currently diagnosed and undiagnosed 1 million people in the US living with AAA between the size of 4.0 and 5.0cm in diameter. Note the US only represents 25.6 percent of the world AAA market.
 
Chrona Sleep’s proprietary sleep therapy technology applies acoustic neuromodulation to enhance sleep and neuroplasticity, targeting more than 113 million sleep-deprived Americans. The market is expected to experience explosive growth with projections of one billion sleep therapy devices to be sold in 2020.
 
Lighthill Medical is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. Over 700,000 individuals globally are diagnosed with liver cancer alone every year and 85 percent are non-resectable, which equates to 573,000 individuals who are potential candidates for targeted therapy. This represents a $340M market opportunity.
 
Nespiro has developed a new data-driven solution for mechanical ventilation weaning and prediction of post-extubation complications utilizing a proprietary open-loop algorithm along with additional sensor inputs across the thoracic cavity. As an accessory product business model, Nespiro’s market is an estimated $192M in the US specific to disposable components alone. 

For more information about TMP and its portfolio of companies please visit www.telluridemedicalpartners.com or contact TMP’s CFO, Bryan Ziegler, via email (bziegler@telluridemp.com).
 

About Telluride Medical Partners LLC
Headquartered in Mesa, AZ, Telluride Medical Partners LLC was founded in 2016 by Eric Wells and is comprised of business entrepreneurs and medical device startup experts focused on bringing disruptive medical device technologies to market. With a cohort of five medical device companies, Telluride Medical Partners is quickly expanding and serving clients worldwide. For more information visit www.telluridemedicalpartners.com. 

TMP Attends Strategic Meetings

It has been a successful week of networking for Telluride Medical Partners and its team. Eric Wells, CEO, attended strategic meetings in San Francisco, CA during the elite 36th Annual J.P. Morgan Healthcare Conference, connecting with industry influencers and leaders while promoting Telluride Medical Partners and its portfolio of companies.

“It has been a busy but very productive week,” stated Wells. “As we continue to advance each company, it is imperative to stay connected with medical device experts and industry influencers to continue to drive interest and market our technologies," stated Wells.

Wells also attended the world’s gathering place this week for all those who thrive on the business of consumer technologies, CES, promoting TMP’s sleep therapy technology, Chrona. Owned and produced by the Consumer Technology Association, CES attracts the world's business leaders and pioneering thinkers specific to consumer electronics. 

"CES is certainly the show of shows when it comes to consumer electronics," stated Wells. "It was exciting to see all of the new technologies while networking with industry leaders who are very interested in TMP's disruptive sleep therapy technology." To learn more about Chrona click here.

TMP Joins AdvaMed

 
0d45e3f.png
 

Telluride Medical Partners is pleased to announce that it is a member of the Advanced Medical Technology Association (AdvaMed), a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. 

“We are thrilled to be a part of this elite group that acts as the common voice for companies producing medical devices, diagnostic products and health information systems,” says Eric Wells, CEO of Telluride Medical Partners. “As a company advancing innovative medical device technologies, it is an honor to be a part of this group that advocates on a global basis for the highest ethical standards, timely patient access to safe and effective products, and economic policies that reward value creation,” states Wells.

AdvaMed promotes competitive policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and access to international markets. To learn more about AdvaMed visit www.advamed.org.

TMP Presents Lighthill Medical at the Texas Life Science Forum

Texas-Life-Science-Forum.png

On Tuesday, November 7, Telluride Medical Partners presented one of their portfolio companies, Lighthill Medical, at the must-attend Texas Life Science Forum in Houston, TX.

“The Texas Life Science Forum is a premier life science event in Texas,” says Eric Wells, CEO of Telluride Medical Partners. “As a presenting company, this was a great opportunity for Telluride Medical Partners to further expose Lighthill Medical to potential investors, science companies, entrepreneurs, investment professionals, big pharma as well as business executives in the life science industry,” says Wells.

IMG_1471.JPG

Lighthill Medical, managed by Telluride Medical Partners, is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. The Lighthill Medical family of catheters utilizes a proprietary, all-in-one form factor, along with temporary occlusion, to significantly reduce the time and costs associated with targeted cancer treatments while maintaining clinical safety and efficacy.

To learn more about Lighthill Medical and investment opportunities, click here.

Nectero Medical Closes $1 Million Bridge Round Over-Subscribed

 
Nectero Logo.png
 

Nectero Medical, Inc., a Telluride Medical Partners portfolio company, announced today that it has closed $1 million of convertible notes as part of a bridge financing following its acquisition of Vatrix Medical, Inc. on April 28, 2017.

“This is great news for Nectero Medical and its stakeholders”, states Eric Wells, CEO of Telluride Medical Partners. “This new capital will allow Nectero Medical to take its patented technology that combats abdominal aortic aneurysms (AAA) to the next commercial milestone, further de-risking the investment for strategic partners, adding value to the company for investors, and providing hope for a new clinical treatment to patients living with AAA,” says Wells.

The convertible note financing, originally offered at $750,000, drew strong interest from investors based on the disruptive technology and promising early-stage in-vivo test results. The company was able to close the round over-subscribed by 33% and secured key, strategic relationships with investors in both Germany and China.

Nectero Medical has developed a technology that prevents and treats vascular aneurysms, a fatal disease that causes the walls of blood vessels to expand, weaken, and ultimately rupture. Currently, the sole treatment for such aneurysms is surgical intervention, and only five percent of patients are candidates for this high-risk procedure. Nectero Medical’s minimally invasive treatment, AAvert, is targeting the unmet need of watchful, waiting and contra-indicted patients, worth $6B today.

Capture Vascular Continues with New Clinical Cases for its MegaVac Mechanical Thrombectomy System

Capture Vascular, Inc. (Capture) recently completed three successful clinical cases using its proprietary MegaVacTM Mechanical Thrombectomy System-ATK.
 
The first case involved a 42-year-old male patient with a target treatment area of the right leg, above and below the knee. Overall the MegaVacTM Mechanical Thrombectomy System was noted that it worked both easy and well and the procedure was marked successful.
 
The second case involved a 62-year-old female patient with a target treatment area of the left leg above the knee. Again the system was noted as working both easy and well where the procedure was not only successful, but the MegaVacTM Mechanical Thrombectomy System exceeded expectations.
 
The third case involved a 67-year-old male patient with a target treatment area of the left leg, above and below the knee. The MegaVacTM Catheter and ThromboWireTM Clot Retractor both performed well with debris noted in the ThromboWireTM Clot Retractor after removal.
 
Capture will continue to perform clinical cases throughout the coming months as it focuses on adoption of the MegaVacTM Mechanical Thrombectomy System-ATK.
 
The recently expanded device description of the ATK builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel, in addition to being able to pass through other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System-ATK can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“In working through recent clinical experiences we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customer’s needs and execute these device advances,” says Wells.
 
Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. 

--

About Capture Vascular, Inc.
Headquartered in Telluride, Colorado, Capture Vascular, Inc. is a Medical Device development company that was founded in May of 2013 to pursue the development and commercialization of innovative medical devices. Capture Vascular’s platform technology is the MegaVacTM Mechanical Thrombectomy System that offers several unique features in one simple, efficient, and effective device. Capture Vascular, Inc. is managed by Telluride Medical Partners LLC. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

Dr. Richard Fulton Steps Down as Chief Medical Officer

Dr. Richard Fulton announced today that he is stepping down from his role as Chief Medical Officer at Telluride Medical Partners.

An esteemed medical practitioner who practiced radiology and interventional radiology for 30 years prior to joining TMP, Dr. Fulton is a prolific inventor with 50-plus issued patents as well as a number of successfully commercialized medical devices including Capture Vascular’s MegaVac Mechanical Thrombectomy System. He has dedicated his post practice life to inventing novel, easy-to-use, and cost-effective devices and products designed to address a wide-range of medical conditions and treatment dilemmas.

“We are grateful to have had Dr. Fulton as part of the TMP team and respect his decision to spend more time with his family”, states Eric Wells, CEO of TMP.

Dr. Fulton will continue to sit on the board for both Capture Vascular and Awestruck Dental, two companies he founded over the last half decade. A true idea-man and passionate inventor, Dr. Fulton will also continue to work on new medical devices outside of TMP.

“We wish Dr. Fulton all of the best of luck with his future endeavors and we thank him for his time serving as Chief Medical Officer at Telluride Medical Partners,” says Wells.

Capture Vascular, Inc. Secures Updated FDA 510(k) Clearance

Capture Vascular Inc. (Capture), a Telluride Medical Partners company, announced today that it has received updated FDA 510(k) clearance that expands the device description for its proprietary MegaVacTM Mechanical Thrombectomy System.

“In working through recent clinical experiences, we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customers needs and execute these device advances,” says Wells.

The expanded device description builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“We are confident that Vascular Surgeons, Interventional Cardiologists and Interventional Radiologists will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” says Wells.

Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.